CD8A and neoplasm: When mice were vaccinated prophylactically or therapeutically after inoculation with Hepa1-6 tumor cells expressing MPFG and HLA-A2, Lm-MPFG treatment led to reduced tumor burden and increased tumor-free survival in comparison to a control Lm. The anti-tumor efficacy of Lm-MPFG correlated with increased infiltrations of MPFG-specific CD8+ T cells and increased cytolytic potential of CTLs.